Foreign Funds Enter Nationwide Hospital Operation And Management
This article was originally published in PharmAsia News
Executive Summary
Hong Kong-listed Golden Meditech has paid HK$830 million to purchase 70 percent of Daopei, China's largest blood disease specialist hospital. At the same time, the firm will gain business licenses and knowledge for national hospital operation and management through its 60 percent acquisition of Jianliang Hospital Management Co., which is the first foreign-owned enterprise qualified to run hospitals nationwide. The deal marks the entry of foreign funds into the sector. The acquisition will allow Golden Meditech to form a complete health care chain and optimize its business network in China's interior region. It will also bring synergy to its health care service, umbilical cord blood hematopoietic stem cell storage and application, as well as medical equipment production and sales. (Click here for more - Chinese Language)
You may also be interested in...
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.